相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
- 库存:
99
- 供应商:
爱必信(上海)生物科技有限公司
- CAS号:
2135600-76-7
- 规格:
50mg/5mg
| 规格: | 50mg | 产品价格: | ¥37706.0 |
|---|---|---|---|
| 规格: | 5mg | 产品价格: | ¥7277.0 |
| 公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:LSZ-102 产品别名:见爱必信官网 英文别名:LSZ-102 靶点:ERR CAS:2135600-76-7 纯度:98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述:LSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC50 of 0.2 nM. 溶解性: 体外研究: LSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC50 of 0.2 nM and currently in Phase I/Ib trials for the treatment of ERα positive breast cancer. LSZ-102 induces significant degradation of ERα after 24 h, when given as a 10 μM solution to MCF-7 cells. Robust inhibition of cell proliferation in MCF-7 cells is observed upon incubation with LSZ-102 with a half inhibitory concentration of 1.7 nM. Results demonstrate that LSZ-102 effectively inhibits the estrogen-induced activation of the ERE-luciferase reporter using charcoal-stripped serum treated with E2 with IC50 of 0.3 nM. 体内研究:LSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC50 of 0.2 nM and currently in Phase I/Ib trials for the treatment of ERα positive breast cancer. LSZ-102 induces significant degradation of ERα after 24 h, when given as a 10 μM solution to MCF-7 cells. Robust inhibition of cell proliferation in MCF-7 cells is observed upon incubation with LSZ-102 with a half inhibitory concentration of 1.7 nM. Results demonstrate that LSZ-102 effectively inhibits the estrogen-induced activation of the ERE-luciferase reporter using charcoal-stripped serum treated with E2 with IC50 of 0.3 nM.
产品信息订购:
absin,您身边的科研百宝箱 |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Bull,2020, 36(3):199‒201] 图 3 AAV1 顺向跨突触标记 [J Neurosci,2020,Apr 15;40(16):3250-3267] 图 4 rAAV2-retro 逆行非跨突触标记 [Neuron, 2016, 92(2):372-382] 可跨血脑屏障的 AAV 血清型⸺AAV-PHP.S、AAV-PHP.B、AAV-PHP.eB、PG008、AAV9P801、VCAP-101、VCAP-102 血脑屏障(BBB)的存在对中枢神经系统(CNS
-101.8 60.1-61.7 10.8-11.4 27.3-28.7 豚鼠 cm 98.5-102.7 58.4-59.6 4.3-4.9 35.8-37.2
124 88 0.25 0.30 123 87 61 0.30 0.35 110 90 64 102 45 0.35 0.40 85 70 100 50 108 78 35 0.40 0.45 118 68 101 55 105 79 39 108 86 62
技术资料暂无技术资料 索取技术资料






![(S)-3,4-二氢-4-羟基-2-(3-甲氧丙基)-2H-噻吩并[3,2-E]-1,2-噻嗪-6-磺酰胺 1,1-二氧化物,154127-42-1](https://img1.dxycdn.com/2022/1124/366/0935076448977474853-14.jpg!wh200)

